Claudio Giuliano
Helsinn (Switzerland)(CH)
Publications by Year
Research Areas
Nausea and vomiting management, Regulation of Appetite and Obesity, HIV/AIDS drug development and treatment, Anesthesia and Sedative Agents, Hepatitis C virus research
Most-Cited Works
- → Potent Inhibitors of Subgenomic Hepatitis C Virus RNA Replication through Optimization of Indole-N-Acetamide Allosteric Inhibitors of the Viral NS5B Polymerase(2005)86 cited
- → Discovery of (7R)-14-Cyclohexyl-7-{[2-(dimethylamino)ethyl](methyl) amino}-7,8-dihydro-6H-indolo[1,2-e][1,5]benzoxazocine-11-carboxylic Acid (MK-3281), a Potent and Orally Bioavailable Finger-Loop Inhibitor of the Hepatitis C Virus NS5B Polymerase(2010)66 cited
- → Netupitant PET imaging and ADME studies in humans(2013)57 cited
- → New ghrelin agonist, HM01 alleviates constipation and L‐dopa‐delayed gastric emptying in 6‐hydroxydopamine rat model of Parkinson's disease(2014)57 cited
- → Ghrelin receptor inverse agonists as a novel therapeutic approach against obesity‐related metabolic disease(2017)48 cited
- → An Easy Procedure for the Highly Regioselective Conversion of Epoxides to Halohydrins(1992)36 cited
- → Oral Treatment with the Ghrelin Receptor Agonist HM01 Attenuates Cachexia in Mice Bearing Colon-26 (C26) Tumors(2017)36 cited
- → Synthesis and evaluation of novel phosphoramidate prodrugs of 2′-methyl cytidine as inhibitors of hepatitis c virus NS5B polymerase(2009)34 cited
- → The ghrelin receptor agonist HM01 mimics the neuronal effects of ghrelin in the arcuate nucleus and attenuates anorexia-cachexia syndrome in tumor-bearing rats(2016)32 cited
- → Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations(2023)32 cited